Company ProfilePremium

Aspen Pharmacare Holdings Limited

Company Profile Analysis

Ticker: APN.JO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Aspen Pharmacare Holdings Limited - Company showcase

Year Founded & Workforce

1997

9,161 Employees

Aspen Pharmacare Holdings Limited logo

Aspen Pharmacare Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Aspen Pharmacare Holdings Limited Overview

FY2023 is from the sustainability supplement. FY2025 is from the Profile's Handbook (2025 Issue 2). FY2024 and post-divestment FY2026 headcounts were not captured. Third-party data aggregators show 8,867 and 9,557, and these are not reconcilable.

Aspen Pharmacare is Africa's largest pharmaceutical company. It is a JSE-listed specialty and branded multinational, run by its co-founder and Group CEO Stephen Saad. It operates through two segments. Commercial Pharmaceuticals (about 73% of FY2026 continuing revenue) markets post-patent branded prescription, OTC and hospital injectable medicines in emerging and developed markets. Manufacturing (about 27%) runs sterile finished-dose (FDF), oral and API plants in South Africa, France and the Netherlands, among other sites, and serves both internal and third-party contracts. FY2026 was a reset year. The R28bn sale of APAC to BGH Capital moved the group from about R31bn of net debt to net cash. Restructuring of the sterile plants in France and South Africa repaired Manufacturing profitability after an mRNA contract was lost. Mounjaro in South Africa became the main growth driver in Commercial Pharma. The investment case now depends on GLP-1s (in-licensed tirzepatide marketing and its own generic semaglutide), sterile capacity fill (insulin, vaccines, GLP-1) and capital returns.


Company's own description

Aspen describes itself as a global specialty and branded pharmaceutical company. It says it improves patient health through high-quality, affordable medicines, is active at every stage of the value chain, and is diversified by geography, product and manufacturing capability (aspenpharma.com investor hub). Its stated strategy has three parts: build product portfolios that achieve organic growth, build a differentiated portfolio of relevant IP, and use complex manufacturing capability plus a globally integrated supply chain to create value and enable access to medicines (investor hub, 2026). Its purpose statement is to improve the health and quality of life of patients. The corporate credo is "Healthcare. We Care."

Independent characterisation

In practice Aspen has three economic engines.

  1. A brand-acquisition and in-licensing commercial platform (Commercial Pharmaceuticals). Since 1997 Aspen has bought mature, off-patent or non-core brands from multinationals, including GSK, AstraZeneca, MSD, Viatris and Sandoz. It markets them through its own affiliates, mainly in emerging markets: Sub-Saharan Africa, the Middle East, Latin America and China. It increasingly also distributes innovator products in South Africa and Sub-Saharan Africa under long-term agreements with Eli Lilly and Boehringer Ingelheim. Revenue is product sales, priced under regulated systems such as South Africa's Single Exit Price and China's volume-based procurement (VBP). There is no material subscription or licensing-fee income.

  2. A multi-site manufacturing business (Manufacturing). This makes FDF products (sterile injectables, oral solids, liquids, semi-solids) and APIs, including hormones and specialised chemistry at Oss (Netherlands) and Fine Chemicals Corporation (Cape Town), plus heparin, now on a working-capital-light toll model. Revenue comes from contract manufacturing (CMO/CDMO) for third parties, internal supply and API sales. This segment carries Aspen's largest fixed-cost and execution risk, which became visible when the mRNA contract was lost in FY2025.

  3. An emerging GLP-1 and specialty access franchise. Aspen distributes Lilly's Mounjaro in South Africa and Sub-Saharan Africa and holds licensed IP for generic semaglutide, approved in Canada in July 2026. It has also secured access licences such as MSD's alimatravir for HIV prevention (July 2026) and Serum Institute paediatric vaccines (2022).

Revenue model mix (FY2025, total operations)

Revenue typeFY2025 ZAR MnShare of group (%)Basis
Branded product sales – Prescription12,51928.9FY2025 segmental analysis
Branded product sales – OTC9,81222.6FY2025 segmental analysis
Branded product sales – Injectables9,88522.8FY2025 segmental analysis
Manufacturing – FDF (third-party and contract)5,09911.8FY2025 revenue analysis
Manufacturing – API4,71810.9FY2025 revenue analysis
Manufacturing – Heparin1,3303.1FY2025 revenue analysis
Total43,363100.0—

Subscription and licensing-fee revenue is not separately disclosed and appears immaterial.

Value-chain position, customers and end-markets

Value chain: Aspen covers API synthesis, FDF manufacture (sterile and non-sterile), regulatory registration, marketing and distribution. Upstream discovery R&D is limited; the group relies on in-licensing and acquired IP.

Customer types: - Public-sector tender buyers, such as South African state ARV and insulin tenders and China's VBP.

  • Private wholesalers and pharmacies (OTC and prescription).

  • Hospitals (anaesthetics and injectables).

  • Multinational pharma contract customers (FDF and API toll and contract manufacturing).

  • Multilateral buyers for vaccines (the target for the Serum Institute and Africa CDC frameworks).

End-markets: anaesthesia, thrombosis, oncology (legacy cytotoxics), metabolic/diabetes and obesity (Mounjaro, semaglutide, insulin), pain and central nervous system (Lyrica, Celebrex in Latin America), consumer health and OTC, infectious disease (HIV, vaccines) and hormones (API).

Strategy

Stated strategy (paraphrased from FY2025–FY2026 disclosures)

  1. Build sustainable organic growth in Commercial Pharmaceuticals, focused on emerging markets and supported by multinational partnerships (Lilly, Boehringer Ingelheim, Viatris, Sandoz).

  2. Monetise the GLP-1 opportunity through two routes: in-licensed branded products (Mounjaro) and Aspen's own and licensed generic semaglutide IP. These feed both commercial sales and manufacturing volumes.

  3. Restore and fill Manufacturing capacity. This means reshaping loss-making sterile FDF plants, commercialising insulin and vaccines, and winning third-party CDMO and API contracts.

  4. Unlock sum-of-the-parts value. APAC was sold at about 11x FY2025 EBITDA. The board says the share price does not fully reflect intrinsic value (SENS, 29 May 2026).

  5. Capital discipline: pay dividends at 20% of NHEPS, deleverage, then use share buybacks to increase shareholder returns (FY2026 prospects).

Initiatives in the last 24 months

InitiativeDateDescriptionTarget / statusSource
China reshapeFY2025–FY2026Integration of Sandoz China; discontinue unprofitable productsRestructuring about R0.5bn plus R0.3bn inventory write-offs (FY2025). Margin accretive in FY2026.FY2025 and FY2026 results
Sterile FDF reshape (France and South Africa)2025–2026Match resources to contracts on handR695m restructuring in H1 2026. Sterile FDF delivered R1.2bn of the R1.7bn FY2026–FY2027 uplift guidance in FY2026. Guidance raised to R2.2bn.FY2026 results
Group efficiency and value-enhancement projectsFY2026Projects across the groupR2.3bn restructuring cost in FY2026FY2026 results
GLP-1: generic semaglutide2024–2027Own and licensed IP; multi-dose pen and autoinjector; production in South Africa and FranceCanada approved (Jul 2026). About 20 registrations pending (Brazil, South Africa and others). Global rollout from FY2027.FY2025 results; Business Day (2 Sep 2026)
GLP-1: Mounjaro expansion2025–2026Rollout across Sub-Saharan AfricaNigeria and Kenya registrations pendingBusiness Day (2 Sep 2026)
Insulin contractCommercial from May 2026Human insulin technology transfer to GqeberhaMore than R1bn revenue targeted in FY2027FY2025 and FY2026 results
Vaccines2022–2026+Serum Institute products; Africa CDC demand frameworkSAHPRA/WHO approvals pending. Africa CDC framework in "advanced discussions" (May 2026).FY2025 results; Aspen release (12 May 2026)
HIV prevention accessJul 2026MSD alimatravir licence covering 129 countriesDependent on Phase III results and regulatory approvalBusiness Report (24 Jul 2026)
APAC divestmentDec 2025 – May 2026Sale to BGH CapitalCompleted; net cash achievedSENS 29 May 2026
Share buybacksMay–Aug 2026Open-market repurchasesR0.5bn at an average of about R148.17 per shareDaily Investor (Sep 2026)
Sustainability (Mandela Day and others)OngoingSocial investmentMore than 920,000 beneficiaries reported (2026)aspenpharma.com news

Medium-term targets and guidance (FY2027)

Guidance itemTargetSource
Group normalised EBITDA (CER)At least R9bn (versus about R7.7bn in FY2026)FY2026 results
NHEPS growth (CER)"Substantial double-digit", quantified on the call as more than 50%FY2026 results; Investing.com transcript
Net interest savingsAbout R1.2bnFY2026 results
Commercial PharmaMid-single-digit CER growth in revenue and EBITDA, excluding GLP-1 rollout upsideFY2026 results
Manufacturing normalised EBITDA (CER)More than double FY2026 (i.e. above R1.66bn)FY2026 results
Sterile FDF cumulative EBITDA uplift (FY2026–FY2027)Raised from R1.7bn to R2.2bnFY2026 results
APIReturn to growth on new third-party contractsFY2026 results
Free cash flowStronger than FY2026Quartr summary

Products & Services

Aspen does not publish a complete SKU-level catalogue in its condensed results. The list below includes only brands and offerings named in the filings and announcements reviewed. Launch years, specifications and pricing are given only where disclosed.

Commercial Pharmaceuticals — Injectables (hospital and specialty)

Product / franchiseDescriptionTarget customerStatus / notesSource
Mounjaro (tirzepatide)Lilly's GIP/GLP-1 agonist for type 2 diabetes and chronic weight management. Aspen promotes and distributes it under licence in South Africa and other Sub-Saharan African markets.Diabetes and obesity patients; private payersLaunched Dec 2024 (T2D). KwikPen approved 2025. Weight-management indication later approved. Registration pending in Nigeria and Kenya. Saad said on the Sep 2026 call that Mounjaro drove about 40% of group growth.Business Day (2 Sep 2026; 28 Oct 2025); FY2025 results
Diprivan (propofol)Anaesthetic from the AstraZeneca anaesthetics portfolioHospitalsAffected by slower post-VBP recovery in China. Impairment in FY2025.FY2025 results note L
Naropin (ropivacaine)Local anaesthetic from the AstraZeneca portfolioHospitalsEEA rights sold to Sandoz (2024). The post-VBP recovery was better than expected, leading to an impairment reversal in FY2025.SENS 4 Dec 2023; FY2025 note L
Fraxiparine (nadroparin)Low-molecular-weight heparin from the GSK thrombosis businessHospitalsChina VBP pressure; impaired in FY2025FY2025 note L
GSK anaesthetics portfolioAnaesthesia products, including Nimbex and Tracrium outside the EEAHospitalsCompetition and price pressure; impaired in FY2025FY2025 note L
Sandostatin (octreotide)Acromegaly and neuroendocrine tumour therapy, acquired with Sandoz ChinaSpecialist hospitals, ChinaPart of about R1.8bn of annual sales addedAspen release (Dec 2023)
Aclasta (zoledronic acid)Bone disease and osteoporosis infusion, acquired with Sandoz ChinaHospitals, ChinaAcquired 2024Aspen release (Dec 2023)
VoriconazoleAntifungal, acquired with Sandoz ChinaHospitals, ChinaAcquired 2024Aspen release (Dec 2023)
Aspen-Semaglutide (generic Ozempic)Generic semaglutide injection for type 2 diabetes, in multi-dose pen and autoinjector formatsDiabetes patients in early patent-expiry marketsHealth Canada approval on 20 Jul 2026. Launch depends on API supply from Dr. Reddy's. About 20 further registrations pending, including Brazil and South Africa. Bigger volumes are planned from the South African sterile plant.FilingReader (20 Jul 2026); Business Day (2 Sep 2026); Medical Dialogues (21 Jul 2026)

Commercial Pharmaceuticals — Prescription

Product / franchiseDescriptionRegionSource
Viatris Latin America portfolio: Lyrica (pregabalin), Celebrex (celecoxib), Viagra (sildenafil), Lipitor (atorvastatin)Mature global brands acquired for Latin America in 2023 for about US$280m / R5.3bnAmericasBusiness Day (4 Apr 2024); H1 2024 SENS
Lilly franchise (Sub-Saharan Africa)Distribution and promotion of Lilly products. It added to Africa Middle East Prescription growth in FY2025.Africa Middle EastFY2025 results; H1 2024 SENS
Boehringer Ingelheim South Africa portfolioLong-term distribution and promotion agreement, effective 1 Sep 2025South AfricaFY2025 results
Specialist global brandsNiche specialty products; three products impaired in FY2025GlobalFY2025 note L
Legacy cytotoxics: Alkeran, Leukeran, Lanvis, Myleran, PurinetholOff-patent haematological oncology drugs, subject to binding EC price commitments until about 2031Europe and globalVBB (Feb 2021)
MSD businessPortfolio acquired from MSD; one product impaired in FY2025GlobalFY2025 note L
ARVs and public-sector chronic medicinesGeneric antiretrovirals supplied through South African state tenders. Brand-level detail was not captured.South AfricaTimesLive (Jul 2026)
Alimatravir (MK-8527), licensedInvestigational once-monthly oral HIV-1 prevention pill (Phase III) under an MSD voluntary licence covering 129 countries, including all of AfricaAfrica and low/middle-income countriesBusiness Report (24 Jul 2026)

Commercial Pharmaceuticals — OTC (consumer health)

ItemDetailSource
GSK OTC brandsLegacy consumer brands bought from GSK. Impairment reversal of R153m in FY2025 because the outlook improved.FY2025 note L
GSK classic brandsMature consumer and Rx brands. Four products impaired in FY2025 because of competition.FY2025 note L
ELIZ productsProduct group with an impairment reversal of R88m in FY2025FY2025 note L
Africa Middle East OTCR3,746m revenue in FY2025 (+5%)FY2025 results
Australasia OTCR2,448m revenue in FY2025 (+5% CER). Divested with APAC on 29 May 2026.FY2025 results

Brand-by-brand OTC names for South Africa were not captured in the documents reviewed.

Manufacturing offerings

OfferingDescriptionSitesStatus / notesSource
Sterile FDF contract manufacturingVials, ampoules, pre-filled syringes and pens; aseptic fill-finishGqeberha (South Africa); Notre-Dame-de-Bondeville (NDB, France)Reshaped in FY2026 (R2.3bn restructuring across the group). Sterile FDF EBITDA uplift guidance raised to R2.2bn cumulative over FY2026–FY2027.FY2026 results
Human insulin contractContract manufacture of human insulin after technology transferGqeberha sterile plantSAHPRA approval received. Commercialisation began in May 2026. Revenue guidance was R0.3bn for FY2026, rising to more than R1bn in FY2027.FY2025 and FY2026 results
Serum Institute vaccinesPneumococcal, rotavirus, polyvalent meningococcal and hexavalent vaccines, made from Serum bulk drug substanceGqeberhaTen-year deal (2022). Regulatory approvals from SAHPRA and WHO are pending. Sales are possible from calendar 2026.SENS 31 Aug 2022; FY2025 results
GLP-1 sterile productionSemaglutide pens and autoinjectors for its own commercial useGqeberha and NDBOnboarding volumes following the semaglutide launchesFY2025 results; Medical Dialogues
API (Aspen API / Oss)Hormones and specialised APIs; CDMO servicesOss (Netherlands); FCC (Cape Town)FY2025 API revenue R4,718m (-8%). Expected to return to growth in FY2027 on new third-party contracts.FY2025 and FY2026 results
HeparinHeparin API under a working-capital-light toll modelEurope CISFY2025 revenue R1,330m (-65%)FY2025 results
mRNA fill-finish (terminated)Manufacturing and technology agreement for mRNA productsSterile FDFAbout R1.5bn contribution in H1 2025, then disputed. €25m settlement in Oct 2025. mRNA assets impaired by R753m.FY2025 results; H1 2026 results

Pricing model. Commercial products are priced under national regulatory regimes: South Africa's single exit price, China's VBP tenders and European reimbursement systems. Manufacturing is priced per contract (unit price, toll fees, take-or-pay where negotiated). No pricing schedules are publicly disclosed.

Financial Narrative

Income statement and per-share data

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentSub-segments / contentsNotes

Commercial Pharmaceuticals

Prescription; OTC; Injectables. Reported by customer geography: Africa Middle East, Americas, Asia, Europe CIS, and Australasia until FY2025.

Australasia and Asia ex-China (APAC) moved to discontinued operations in H1 2026

Manufacturing

Finished Dose Form (sterile and non-sterile); Active Pharmaceutical Ingredients; Heparin. Reported by geography of manufacture.

FDF Australasia (Dandenong) was divested with APAC

Other

One-off compensation or insurance income not allocated to segments (R549m in FY2024; nil in FY2025)

FY2025 enhanced segmental disclosure

Revenue by Segment

SegmentFY2022FY2023FY2024FY2025FY2026

Prescription (ZAR Mn)

——11,38012,519—

OTC (ZAR Mn)

——9,7069,812—

Injectables (ZAR Mn)

——9,4849,885—

Commercial Pharmaceuticals total (ZAR Mn)

27,70030,12130,57032,21625,405

Manufacturing (ZAR Mn)

10,94810,58814,13611,1479,465

Group revenue (ZAR Mn)

38,60640,70944,70643,36334,870

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Results by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Commercial Pharmaceuticals normalised EBITDA (ZAR Mn)

8,8598,923—

Manufacturing normalised EBITDA (ZAR Mn)

1,847668828

Other (ZAR Mn)

5490—

Commercial Pharmaceuticals EBITDA margin (%)

29.027.7—

Manufacturing EBITDA margin (%)

13.16.08.7

Commercial Pharmaceuticals gross margin (%)

59.458.1—

Manufacturing gross margin (%)

9.23.7—

Prescription gross margin (%)

60.961.8—

OTC gross margin (%)

58.758.3—

Injectables gross margin (%)

58.253.2—

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2024FY2025FY2026

Commercial Pharma revenue growth, reported (%)

—5—

Commercial Pharma revenue growth, CER (%)

—105

Manufacturing revenue growth, reported (%)

—-21-10

Commercial Pharma EBITDA growth, CER (%)

—1013

Manufacturing EBITDA growth, CER (%)

—-6221

Commercial Pharma share of group revenue (%)

68.474.372.9

Manufacturing share of group revenue (%)

31.625.727.1

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (ZAR Mn)

38,60640,70944,70643,36334,870

Gross profit (ZAR Mn)

——19,45419,129—

Gross margin (%)

——43.544.143.0

Operating profit (ZAR Mn)

——6,9981,437—

Operating margin (%)

——15.73.3—

Normalised EBITDA (ZAR Mn)

11,01211,10011,2559,5917,700

Normalised EBITDA margin (%)

28.527.325.222.122.1

Profit/(loss) before tax (ZAR Mn)

——5,714-123—

Tax (ZAR Mn)

——1,310960—

Net profit/(loss) for the year (ZAR Mn)

——4,404-1,083—

Net margin (%)

——9.9-2.5—

Basic and diluted EPS (ZAR cents)

1,432.31,176.9991.4-243.9—

HEPS (ZAR cents)

1,461.21,405.41,356.6792.1—

NHEPS, total operations (ZAR cents)

1,627.61,498.51,492.11,055.8—

NHEPS, continuing operations (ZAR cents)

———659.2801.5

Dividend per share (ZAR cents)

326342359211232

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (ZAR Mn)

——139,063135,893—

Cash and cash equivalents (ZAR Mn)

——12,3376,409—

Borrowings – current (ZAR Mn)

——11,3144,612—

Borrowings – non-current (ZAR Mn)

——25,14131,508—

Total borrowings (ZAR Mn)

——36,45536,120—

Borrowings less cash, computed (ZAR Mn)

——24,11829,711—

Net debt, company-reported (ZAR Mn)

16,10022,200—31,200-800

Shareholders' equity (ZAR Mn)

—86,23684,86184,893—

Goodwill (ZAR Mn)

——5,6965,202—

Intangible assets (ZAR Mn)

——66,02667,212—

Goodwill plus intangibles (ZAR Mn)

——71,72272,414—

Inventories (ZAR Mn)

——18,00218,009—

Working capital, current assets less current liabilities (ZAR Mn)

——19,78421,206—

Net debt / EBITDA, company-defined (x)

———3.2—

Cash Flow and Per-Share Data

MetricFY2023FY2024FY2025FY2026

Cash operating profit (ZAR Mn)

—9,96710,064—

Cash generated from operations (ZAR Mn)

—9,7258,461—

Cash generated from operating activities (ZAR Mn)

—6,2255,159—

Operating cash flow per share (ZAR cents)

1,242.61,401.41,161.9—

Cash conversion rate (%)

—103147—

Capex – PPE (ZAR Mn)

—3,1172,576—

Capex – intangible assets (ZAR Mn)

—2,4182,479—

Total capex (ZAR Mn)

—5,5355,055—

FCF, operating activities less capex, computed (ZAR Mn)

—690104—

Free cash flow before dividends, company-reported (ZAR Mn)

———3,800

Dividends paid (ZAR Mn)

—1,5251,601—

Share buybacks (ZAR Mn)

———500

Treasury shares purchased for incentive schemes (ZAR Mn)

—5668—

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2024FY2025

ROE, net profit / year-end equity (%)

5.2-1.3

ROA, net profit / year-end total assets (%)

3.2-0.8

Current ratio (x)

1.812.21

Debt / equity, total borrowings / equity (x)

0.430.43

Net debt / EBITDA, company-reported (x)

—3.2

Interest cover, normalised EBITDA / interest paid (x)

5.25.8

Asset turnover, revenue / year-end total assets (x)

0.320.32

Days inventory outstanding (days)

260271

Days sales outstanding (days)

103112

Days payables outstanding (days)

150161

Cash conversion cycle (days)

213223

Effective tax rate (%)

22.9—

Revenue by Region

RegionFY2024FY2025

Europe CIS revenue (ZAR Mn)

17,60314,682

Africa Middle East revenue (ZAR Mn)

9,50710,567

Americas revenue (ZAR Mn)

6,7116,843

Australasia revenue (ZAR Mn)

6,6856,311

Asia revenue (ZAR Mn)

4,2004,960

Total revenue (ZAR Mn)

44,70643,363

Region growth (%)

Region growth (%)FY2025 reported (%)FY2025 CER (%)

Europe CIS

-17-15

Africa Middle East

1113

Americas

216

Australasia

-6-1

Asia

1821

Total

-31

Revenue by Region — Africa Middle East

RegionFY2024FY2025

Africa Middle East (ZAR Mn)

9,02110,086

Americas (ZAR Mn)

6,6776,826

Australasia (ZAR Mn)

5,9045,748

Asia (ZAR Mn)

4,1004,850

Europe CIS (ZAR Mn)

4,8684,706

Region Overview

RegionPrescriptionOTCInjectablesTotal CP

Africa Middle East

4,5693,7461,77110,086

Americas

3,3201,3292,1776,826

Australasia

2,3772,4489235,748

Asia

1,2103163,3244,850

Europe CIS

1,0431,9731,6904,706

Total

12,5199,8129,88532,216

Africa Middle East

4,2423,5611,2189,021

Americas

2,8321,4502,3956,677

Australasia

2,6182,4308565,904

Asia

6972913,1124,100

Europe CIS

9911,9741,9034,868

Total

11,3809,7069,48430,570

Business Lines

LineFY2024FY2025

FDF – Europe CIS (ZAR Mn)

4,1314,159

FDF – Australasia (ZAR Mn)

781563

FDF – Africa Middle East (ZAR Mn)

216250

FDF – Asia (ZAR Mn)

100110

FDF – Americas (ZAR Mn)

3417

API – Europe CIS (ZAR Mn)

4,8324,487

API – Africa Middle East (ZAR Mn)

270231

Heparin – Europe CIS (ZAR Mn)

3,7721,330

Revenue by Region (%)

CurrencyFY2024FY2025

Euro share of revenue (%)

3429

South African rand share (%)

1518

Australian dollar share (%)

1413

Chinese yuan share (%)

57

US dollar share (%)

66

Mexican peso share (%)

54

Brazilian real share (%)

54

British pound share (%)

22

Canadian dollar share (%)

22

Colombian peso share (%)

12

Other currencies share (%)

1113

Share Price History

DatePrice (ZAR)ContextSource

1 Sep 2022

About 156

Technical breakout level cited

TradingView commentary

Apr 2024

About 220 (implied)

Market cap R98.2bn

Business Day (4 Apr 2024)

3 Sep 2024 (open)

About 237 (implied)

Before the FY2024 results sell-off

Daily Investor (Saad stake valuation)

3 Sep 2024 (close)

About 208 (implied)

After the FY2024 results

Daily Investor

17 Sep 2025

About 101

After the FY2025 loss; 1-year change -47%

Simply Wall St

30 Apr 2026

139.00

Before APAC completion

Fintel

29 May 2026

144.70

+7% on APAC completion

Business Report

Week of 10 Oct 2026

About 160

About R69bn market cap; +40% YTD; more than +60% over 12 months

Business Day (10 Oct 2026)

Valuation Snapshot

MultipleValueBasis

P/E (FY2026 continuing NHEPS 801.5c)

About 20.0x

Derived

P/E (FY2027 guidance: NHEPS growth above 50%, i.e. above about 1,202c)

Below about 13.3x

Derived from guidance

EV/EBITDA (FY2026 continuing about R7.7bn)

About 8.9x

Derived; EV about R68bn, excluding leases

EV/EBITDA (FY2027 target of at least R9bn)

About 7.6x or less

Derived

EV/Sales (FY2026 continuing R34.9bn)

About 1.95x

Derived

P/B

About 0.8x (approximate)

FY2026 equity not captured. FY2025 equity was R84.9bn; tangible NAV/share was R156.46 at Jun 2025 (Business Report).

Dividend yield (232c)

About 1.5%

Derived

Analyst Ratings & Targets

DateConsensus target (ZAR)Source

Sep 2025

120.60

Simply Wall St

Apr 2026

157.08 average (an earlier revision to 146.20 also noted)

Fintel

Undated (2026)

172.67 average across 15 analysts; range 165–183

Traders Union aggregator

Per-Share Data

MetricFY2020FY2021FY2022FY2023FY2024FY2025FY2026

Dividend per share (ZAR cents)

0262326342359211232

Analyst Conclusions

Management guidance (FY2027)

  • Normalised EBITDA of at least R9bn at CER, versus about R7.7bn in FY2026.

  • NHEPS growth above 50% at CER.

  • Net interest savings of about R1.2bn.

  • Commercial Pharma: mid-single-digit growth in revenue and EBITDA, with GLP-1 rollout as upside.

  • Manufacturing EBITDA more than double FY2026.

  • Sterile FDF uplift guidance raised to R2.2bn cumulative.

  • API returns to growth.

  • Stronger free cash flow.

Sources: FY2026 results; Quartr; Investing.com transcript.

Bull case

  1. Operating leverage plus deleveraging compounds per-share earnings. EBITDA of at least R9bn plus about R1.2bn of interest savings supports more than 50% NHEPS growth. On that basis the shares trade at under about 13x FY2027 earnings and about 7.6x EV/EBITDA, with net cash.

  2. Two GLP-1 routes to growth. Mounjaro drove about 40% of FY2026 growth. Generic semaglutide adds a second engine across about 20 filings, including Brazil with independent API supply. It also loads the South African and French sterile plants.

  3. The Manufacturing earnings base is improving. Insulin (above R1bn in FY2027), the sterile reshape (R1.2bn already delivered) and possible Africa CDC vaccine volumes give visible improvement after two volatile years.

Bear case

  1. Manufacturing guidance has a poor track record. COVID vaccine roll-off, the mRNA loss and repeated restructuring (R0.2bn → R0.8bn → R2.3bn) show a history of missed manufacturing targets. A doubling of Manufacturing EBITDA in one year carries high execution risk.

  2. Generic semaglutide may be crowded and low-margin. Nine Canadian filers, Dr. Reddy's being first and Aspen's dependence on Dr. Reddy's API could limit Aspen to a small share at falling prices.

  3. Reported earnings remain exposed to impairments and currency. R72bn of intangibles and goodwill are sensitive to discount rates, tax rates and China VBP. Rand strength has diluted reported results for two years.

Catalysts and monitorables (next 12 months)

  • Canadian semaglutide launch timing, once Dr. Reddy's API supply resumes (late Oct 2026 or later).

  • Brazil and South Africa semaglutide approvals.

  • Mounjaro approvals in Nigeria and Kenya.

  • H1 FY2027 results (about Mar 2027): delivery of Manufacturing EBITDA and insulin revenue.

  • SAHPRA/WHO approval of the Serum vaccines; any signed Africa CDC framework.

  • Size and pace of buybacks; any further sum-of-the-parts transactions.

  • Chair transition at the Dec 2026 AGM; any CEO succession disclosure.

  • Phase III readout for alimatravir (MSD).

  • Rand trajectory against the EUR, CNY, MXN and BRL.

Analyst verdict

Aspen enters FY2027 in better shape than at any point in the past five years. The APAC sale at about 11x EBITDA turned roughly R31bn of net debt into net cash. It also made the sum-of-the-parts argument concrete. The continuing business held a 22.1% normalised EBITDA margin despite losing its highest-margin region. That outcome reflects real repricing and cost work in China and the sterile plants, and it is more than accounting.

Commercial Pharmaceuticals is still a dependable compounder. It grew EBITDA at double-digit CER rates in both FY2025 and FY2026. Mounjaro has changed the economics of the South African business, and the Lilly, BI and MSD agreements show that multinationals view Aspen as the preferred route into Africa.

The investment case now depends on execution in Manufacturing and GLP-1 generics. History argues for caution in both areas. Aspen has repeatedly lost manufacturing profit to events outside its control or to over-optimistic contract assumptions. The Dr. Reddy's API interruption shows how a third party can delay a launch the company has fully prepared. In generic semaglutide, being first to market matters, and Aspen is not first in Canada.

At about R160, the market already prices in a substantial recovery, at about 20x trailing continuing NHEPS. It does not yet price full delivery of the FY2027 guidance, which implies under about 13x forward. The risk–reward is therefore positive but depends on execution. Each R1bn of shortfall in Manufacturing EBITDA would cut roughly a third of the guided earnings growth (derived).

This research supports a constructive, evidence-contingent view. Three things would validate it:

  • H1 FY2027 Manufacturing EBITDA tracking toward more than R1.6bn;

  • a Canadian or Brazilian semaglutide launch by mid-2027;

  • disciplined use of the net cash position, through buybacks or bolt-ons at sensible multiples.

The view would be undermined by:

  • another large one-off restructuring charge;

  • material new impairments;

  • a slowdown in Mounjaro growth as oral and generic GLP-1s enter South Africa.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackground / notesSource

Stephen Bradley Saad

Group Chief Executive, executive director

Co-founder, 1997 to date

BCom (University of KwaZulu-Natal). Earlier built Zurick Pharmaceuticals, which was sold to Prempharm (Adcock). Chair of The Sharks rugby team. Age 61 per company website (2025). Holds about 12.2–12.8%.

BusinessTech (Feb 2025); aspenpharma.com

Sean Capazorio

Group Chief Financial Officer, executive director

Not captured

CA(SA). Prepared the FY2025 results.

FY2025 results

Reginald (RT) Haman

Chief Corporate Officer, executive director

Joined May 2020; CCO from Apr 2021

Left the board on 1 May 2026; resignation effective 31 Jul 2026 (relocation). Reported pay about R13m a year.

Daily Investor (30 Apr 2026)

Michael (Gus) Attridge

Co-founder; chief advisor (former Deputy Group CEO)

Since 1997

Not on the FY2025 director list. Holds about 4.3%.

Daily Investor; Simply Wall St

Roy Campbell

Investor Relations (joined 2026)

2,026

Introduced on the H1 2026 call

Stockalarm transcript

R Khan

Company Secretary

Not captured

—

FY2025 results

Board of Directors

DirectorRoleBoard sinceBackground / notes2026 status

Kuseni D. Dlamini

Independent non-executive Chair

2012 (Chair since 2015)

Former head of Anglo American South Africa

Steps down at the Dec 2026 AGM

Ben (BJ) Kruger

Independent NED; former Lead Independent Director; former Audit & Risk chair

2019

Former co-CEO of Standard Bank Group. Standard Bank NED. University of Pretoria council deputy chair.

Chair-designate from Dec 2026 AGM. Joined Remuneration & Nomination Committee.

Chris (CN) Mortimer

Non-executive director

1999

Legal counsel background; 27-year tenure

Retires Dec 2026

Yvonne (YG) Muthien

Independent NED

Not captured

SA Reserve Bank NED; Rhodes Food Group social and ethics chair

Turns 70 in Sep 2026; term extended one year

Themba (TM) Mkhwanazi

Independent NED

Not captured

Stakeholder and sustainability expertise

Joined Social & Ethics Committee (Jul 2026)

Linda (L) de Beer

Independent NED

Not captured

Not captured

Continuing

N Dongwana

Independent NED

Not captured

Not captured

Continuing

David (DS) Redfern

Independent NED

Not captured

Not captured

Continuing

Stephen Saad

Executive director (Group CEO)

Founder

—

Continuing

Sean Capazorio

Executive director (Group CFO)

Not captured

—

Continuing

Reginald Haman

Executive director

2020/21

—

Left 1 May 2026

Major Shareholders

HolderStake (%)Date / source

Government Employees Pension Fund, via the Public Investment Corporation (PIC)

20.098

SENS notification, 2 Jul 2026

Stephen Saad

12.2–12.8

12.80% at 12 Feb 2025 (Profile's Handbook). He bought a further 853,966 shares for about R101.9m on 7 May 2025 (Simply Wall St). Vendor data varies.

Coronation Fund Managers

5.2–8.0

Simply Wall St (two snapshots differ)

Sanlam Investment Management

4.1–4.9

Simply Wall St

Michael (Gus) Attridge

4.3

Simply Wall St

BlackRock

3.8–4.2

Simply Wall St

Old Mutual Investment Group

3.8

Simply Wall St

The Vanguard Group

3.2

Simply Wall St

Capital Research & Management

2.7–4.9

Simply Wall St

Schroder Investment Management

2.7

Simply Wall St

Competitive Landscape

Competitors by Segment

SegmentCompetitorOverlap

South African prescription and OTC

Adcock Ingram (JSE: AIP; NATCO associate)

Largest local listed peer in OTC, prescription and hospital products

South African and African generics

Cipla (Cipla Medpro South Africa)

Generics, ARVs, public tenders

Global generics and biosimilars, emerging markets

Sandoz

Generics in China and Europe; also a counterparty

Global branded generics

Viatris

Mature brands in Latin America and Europe; also a counterparty

Global generics

Teva

Generics across Europe and emerging markets

Hospital injectables and anaesthetics

Fresenius Kabi

Propofol and injectable anaesthetics

Injectables (MENA and Europe)

Hikma

Sterile injectables, MENA branded generics

Generic GLP-1 (semaglutide)

Dr. Reddy's (also supplier), Sandoz, Teva, Zydus, Alkem and others

Canada and emerging-market semaglutide launches; nine generic filings in Canada

Branded GLP-1

Novo Nordisk (Ozempic/Wegovy; oral Wegovy seeking South African approval)

Competes with Aspen-distributed Mounjaro and generic semaglutide

Sterile CMO/CDMO

Fareva, Delpharm, Recipharm and other European fill-finish CMOs

Third-party sterile contracts for NDB and Gqeberha

African vaccines

Biovac (South Africa), Institut Pasteur de Dakar and others

Africa CDC vaccine localisation agenda

Heparin API

Chinese heparin suppliers (e.g. Hepalink)

Heparin pricing and supply

Peer Comparison FY2025

CompanyFiscal yearRevenueRevenue growthEBITDA / trading marginR&D intensitySource

Aspen (continuing)

FY Jun 2026

R34.9bn

Flat (CER)

22.1% normalised EBITDA

—

FY2026 results

Aspen (total)

FY Jun 2025

R43.4bn

-3% reported / +1% CER

22.1% normalised EBITDA

—

FY2025 results

Sandoz

FY Dec 2025

US$11.1bn

Not captured

21.7% core EBITDA

Not captured

Sandoz FY2025 release (Feb 2026)

Adcock Ingram

FY Jun 2025

R9.76bn

+1%

12.1% trading margin (R1.18bn / R9.76bn, derived)

Not captured

Adcock FY2025 SENS

Adcock Ingram

FY Jun 2026

US$592m

Not captured

Not captured

Not captured

Indian Pharma Post (Aug 2026)

Viatris / Teva / Hikma / Fresenius Kabi

2025—————

“—” = not publicly disclosed.

Company Snapshot

$1,937.2M

Revenue

9,161

Employees

1997

Founded

Durban, South Africa

Headquarters

SWOT Analysis

Strengths

  • Commercial Pharma growth record: FY2025 revenue and EBITDA +10% CER. FY2026 continuing revenue +5% and EBITDA +13% CER (FY2025 and FY2026 results).
  • Balance sheet repaired: Net debt of R31.2bn (Jun 2025) became net cash of about R0.8bn (Jun 2026) after the R28bn APAC proceeds (FY2026 results).
  • Strong in-licensing partner network: Lilly (Mounjaro), BI (from 1 Sep 2025), MSD (alimatravir, 129 countries), Serum Institute (four vaccines, 10 years).
  • Mounjaro momentum: About 40% of group growth in FY2026; category share about 15%→53% in South Africa in 12 months (FY2026 call).
  • Proven ability to realise value: APAC, a 2001 start-up, sold at about 11x FY2025 normalised EBITDA. Profit on sale R2.4bn.
  • High commercial gross margins: Commercial Pharma gross margin 58.1% (FY2025). Prescription 61.8%.

Weaknesses

  • Manufacturing volatility: Manufacturing EBITDA fell from R1,847m (FY2024) to R668m (FY2025) after the mRNA contract loss (FY2025 results).
  • Repeated large non-cash impairments: R4.8bn net impairments (FY2025); R2.3bn (FY2026). Intangibles plus goodwill of R72.4bn (FY2025).
  • Recurring "one-off" restructuring: Restructuring costs of R227m (FY2024), R848m (FY2025) and R2.3bn (FY2026).
  • Working-capital intensity: Cash conversion cycle about 223 days (FY2025, derived). Working capital to revenue 47% (FY2025) and 44% (FY2026).
  • Low returns on equity: ROE 5.2% (FY2024) and -1.3% (FY2025), derived.
  • Key-person concentration: Founder-CEO in post since 1997. No public CEO succession plan in the documents reviewed. The CCO resigned in Apr 2026.

Opportunities

  • Generic semaglutide rollout: Canada approved (Jul 2026). About 20 further registrations, including Brazil and South Africa. Brazil API is from a different supplier to Dr. Reddy's (Business Day, 2 Sep 2026).
  • Sterile capacity fill: Insulin more than R1bn revenue (FY2027 target). Sterile FDF uplift guidance raised to R2.2bn (FY2026 results).
  • African vaccines: Africa CDC framework with potential volumes of hundreds of millions of doses a year (Business Day, 12 May 2026).
  • Mounjaro expansion in Sub-Saharan Africa: Nigeria and Kenya registrations pending; West Africa next (Business Day, 2 Sep 2026).
  • Capital returns: Net cash plus the board's view that shares are undervalued (SENS, 29 May 2026); R0.5bn bought back by Aug 2026.
  • Interest savings: About R1.2bn of net interest savings guided for FY2027 (FY2026 results).

Threats

  • Generic GLP-1 price competition: Nine generic semaglutide filings in Canada (Business Day, 19 Jan 2026). Dr. Reddy's launched first in Canada (May 2026).
  • API supply dependency: Dr. Reddy's semaglutide API impurity issue disrupts Canadian supply until at least late Oct 2026 (Medical Dialogues, 21 Jul 2026).
  • China VBP: Diprivan and Fraxiparine impairments of R1,679m and R1,195m (FY2025 note L).
  • Tax regime changes: QDMTT at 15% in Mauritius added R1.7bn to impairments and raised the effective tax rate (FY2025 results).
  • Currency: Rand strength diluted all FY2026 earnings measures (FY2026 trading statement). EUR was 29% of FY2025 revenue.
  • Regulatory and pricing scrutiny: Binding EC price commitments on cancer drugs (2021, 10-year ceiling). Breach risks a fine of up to 10% of turnover.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
22 Apr 2025SENS discloses a material dispute on an mRNA manufacturing contract; FY2025 Manufacturing EBITDA potentially R2bn lower FY2025 resultsMain cause of the FY2025 earnings downgrade and share de-rating
7 May 2025CEO Saad buys 853,966 shares at up to R119.76 (about R101.9m) Simply Wall StInsider confidence signal
2025 (H2)Saad's cumulative 2025 share purchases exceed R200m Business Day (28 Oct 2025)Insider alignment
Aug 2025First generic semaglutide filing with Health Canada Multibagg (citing Reuters)Start of the GLP-1 regulatory path
21 Aug 2025FY2025 trading statement: a loss per share is expected Daily Investor (21 Aug 2025)Confirms R4.1bn of impairments
1 Sep 2025Boehringer Ingelheim South Africa distribution agreement takes effect FY2025 resultsPortfolio addition
3 Sep 2025FY2025 results: revenue R43.4bn (-3%), normalised EBITDA R9.6bn (-15%), loss R1.1bn, dividend 211cLow point in the earnings cycle
Sep 2025Mounjaro KwikPen (type 2 diabetes) approved in South Africa; weight-management indication pending, later approved FY2025 results; Daily Investor (Sep 2026)Expands the Mounjaro franchise
6 Oct 2025FY2025 dividend paid FY2025 results—
Oct 2025mRNA dispute settled; €25m (about R0.5bn) received in H1 2026 H1 2026 resultsRemoves litigation overhang
28 Oct 2025Annual letter says Mounjaro registrations are under way across Sub-Saharan Africa, with launches in 2026 Business Day (28 Oct 2025)Regional expansion
29 Dec 2025Binding agreement to sell APAC to BGH Capital for A$2.37bn Aspen releaseTransformational deleveraging
15 Jan 2026Stakeholder engagement call on the divestment H1 2026 resultsInvestor communication
19 Jan 2026Canada semaglutide patent protection lapses; nine generic filings at Health Canada Business Day (19 Jan 2026)Competitive intensity in the launch market
Feb 2026Second Canadian semaglutide submission Multibagg (citing Reuters)Regulatory progress
11 Feb 2026H1 business update and trading statement SENS 11 Feb 2026Guides to a "transitional" H1
3 Mar 2026H1 2026 results: revenue R21.1bn (-4%), normalised EBITDA R5.05bn (-13%), NHEPS 574.8c (-21%), net debt R28.6bnConfirms the H2-weighted recovery path
19 Mar 2026APAC transaction circular distributed SENS 29 May 2026Shareholder approval process
21 Apr 2026Further transaction-related SENS (referenced in the completion announcement) SENS 29 May 2026Approval milestone
30 Apr 2026Chief Corporate Officer Reginald Haman resigns (board exit 1 May; role exit 31 Jul) Daily InvestorExecutive bench thins
May 2026Human insulin manufacturing commercialised after SAHPRA approval FY2026 resultsSterile capacity fill; FY2027 revenue above R1bn targeted
12 May 2026Advanced discussions with Africa CDC on a long-term vaccine demand framework Aspen / Africa CDC releasePossible multi-year vaccine volumes
29 May 2026APAC divestment completed; share price +7% to R144.70 SENS; Business Report (31 May 2026)Net debt largely eliminated
May–Aug 2026Share buybacks of R0.5bn at an average of about R148.17 Daily Investor (Sep 2026)First meaningful capital return beyond dividends
2 Jul 2026PIC holding rises to 20.098% FilingReaderLargest shareholder increases its stake
9 Jul 2026Chair succession (Kruger to replace Dlamini), Mortimer retirement, Muthien extension SENS 9 Jul 2026Board renewal
20 Jul 2026Health Canada approves Aspen-Semaglutide; launch depends on Dr. Reddy's API FilingReader; Medical DialoguesFirst regulated-market GLP-1 approval
24 Jul 2026MSD alimatravir licence covering 129 countries Business Report; Bloomberg LawHIV prevention pipeline access
5 Aug 2026UNAIDS welcomes the MSD licences to Aspen and two other African makersReputational and policy support
21 Aug 2026FY2026 trading statement: continuing NHEPS +19% to +24% reported; total EPS 550–620c SENS 21 Aug 2026Pre-announces the earnings recovery
2 Sep 2026FY2026 results: continuing NHEPS 801.5c (+28% CER), net cash about R0.8bn, dividend 232c, FY2027 EBITDA target of at least R9bnInflection confirmed
3 Sep 2026Results call: Mounjaro about 40% of group growth; semaglutide registrations pending in about 20 countries; Brazil API from a different supplier Billionaires.Africa; Business Day (2 Sep 2026)Clarifies GLP-1 trajectory
12 Oct 2026FY2026 dividend paid FY2026 results—
10 Oct 2026Share up about 40% year-to-date and more than 60% over 12 months; about R160, about R69bn market cap Business Day (10 Oct 2026)Re-rating

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

8 charts
Revenue by Segment: Prescription rose from ZAR 11,380 Mn in FY2024 to ZAR 12,519 Mn in FY2025.
Aspen Pharmacare Holdings Limited — Revenue by Segment
Series (ZAR Mn)FY2022FY2023FY2024FY2025FY2026
Prescription——11,38012,519—
OTC——9,7069,812—
Injectables——9,4849,885—
Commercial Pharmaceuticals total27,70030,12130,57032,21625,405
Manufacturing10,94810,58814,13611,1479,465
Group revenue38,60640,70944,70643,36334,870

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Aspen Pharmacare — Reviewed condensed Group financial results FY Jun 2025 (JSE SENS PDF)
  2. Aspen — "Strong execution positions Aspen for sustainable growth" (FY2026 results, 2 Sep 2026)
  3. Aspen — Business update and trading statement FY2026 (SENS, 21 Aug 2026), via Sharenet
  4. Aspen — H1 2026 interim results release (3 Mar 2026)
  5. Aspen — H1 2026 interim results SENS PDF
  6. Aspen — FY2025 results release (3 Sep 2025)
  7. Aspen — Proposed divestment of Aspen APAC (29 Dec 2025)
  8. Aspen — Completion of APAC divestment (SENS, 29 May 2026)
  9. Aspen — FY2023 results release
  10. Aspen — FY2022 results SENS
  11. Aspen — FY2024 results release
  12. Aspen — H1 2024 results SENS
  13. Aspen — Sandoz transactions SENS (4 Dec 2023; 4 Apr 2024) · senspdf.jse.co.za
  14. Aspen — Serum Institute agreement SENS (31 Aug 2022)
  15. Aspen — Africa CDC vaccine partnership release (12 May 2026)
  16. Aspen — Succession and board composition update (SENS, 9 Jul 2026)
  17. Aspen — Investor overview
  18. Business Day — Aspen leads health-care rally (10 Oct 2026)
  19. Business Day — Aspen profit jumps on Mounjaro demand (2 Sep 2026)
  20. Business Day — Aspen eyes Canada generic semaglutide (19 Jan 2026)
  21. Business Day — GLP-1 licence "a coup" (30 Oct 2024)
  22. Business Day — Aspen targets Africa for weight-loss drug expansion (28 Oct 2025)
  23. Business Day — Sandoz China deal (4 Apr 2024)
  24. Quartr — Aspen H2 2026 earnings summary
  25. Investing.com — FY2026 earnings call transcript
  26. Billionaires.Africa — FY2026 call commentary (3 Sep 2026)
  27. EWN — CFO interview, FY2026
  28. Daily Investor — FY2025 loss: H1 2026 · Haman resignation; chair succession; buybacks · dailyinvestor.com · dailyinvestor.com · dailyinvestor.com · dailyinvestor.com
  29. Business Report — APAC completion share move (31 May 2026): MSD agreement (24 Jul 2026) · businessreport.co.za
  30. FilingReader — Health Canada approval: PIC stake · APAC completion; chair succession · filingreader.com
  31. Medical Dialogues — Generic Ozempic approval and Dr. Reddy's API (21 Jul 2026)
  32. Engineering News — H1 2026 business update (12 Feb 2026)
  33. UNAIDS — Alimatravir licences (5 Aug 2026)
  34. Profile's Stock Exchange Handbook 2025 (Issue 2), p.85
  35. Simply Wall St — Ownership; consensus narrative
  36. Fintel — APN price target (Apr 2026)
  37. Traders Union — APN consensus
  38. VBB / Slaughter and May — EC commitments (Feb 2021) · slaughterandmay.com
  39. ethical.org.au — CDP and Sustainalytics data
  40. sustainabilityreports.com — Aspen FY2022–FY2024 report summaries
  41. Sandoz — FY2025 results (Feb 2026), via 1stOncology
  42. Engineering News — Adcock Ingram FY2025 results
  43. Indian Pharma Post — Dr. Reddy's Canada approval: NATCO/Adcock FY2026 · indianpharmapost.com

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.